Boehringer Ingelheim, Eli Lilly Collaborate in Clinical Trial for Metastatic Breast Cancer Combo Therapy
News
Boehringer Ingelheim and Eli Lilly will collaborate on a Phase 1b clinical trial to assess the safety and tolerability of Boehringer Ingelheim’s BI 836845 in combination with Lilly’s abemaciclib (LY2835219) to treat patients ... Read more